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Abstract
Background: Physical disease remains a challenge in patients with schizophrenia. Our objective was to determine
the epidemiological characteristics and burden of physical disease in hospitalized patients with schizophrenia.
Methods: We analyzed the 2004 Spanish National Hospital Discharge Registry, identified records coded for
schizophrenia (295.xx) and characterized the physical diseases using the ICD-9 system and the Charlson Index. We
also calculated standardized mortality ratios (SMRs) versus the general population adjusted by age and calendar
time.
Results: A total of 16, 776 cases (mean age: 43 years, 65% males) were considered for analysis. Overall, 61% of
cases had at least one ICD-9 physical code and 32% had more than one ICD-9 code. The Charlson index indicated
that 20% of cases had a physical disease of known clinical impact and prognostic significance. Physical disease
appeared early in life (50% of cases were 15-31 years of age) and increased rapidly in incidence with age. Thus, for
patients aged 53 years or more, 84% had at least one physical ICD-9 code. Apart from substance abuse and
addiction, the most prevalent diseases were endocrine (16%), circulatory (15%), respiratory (15%), injury-poisoning
(11%), and digestive (10%). There were gender-related differences in disease burden and type of disease. In-hospital
mortality significantly correlated with age, the Charlson Index and several ICD-9 groups of physical disease. Physical
disease was associated with an overall 3.6-fold increase in SMRs compared with the general population.
Conclusions: This study provides the first nationally representative estimate of the prevalence and characteristics
of physical disease in hospitalized patients with schizophrenia in Spain. Our results indicate that schizophrenia is
associated with a substantial burden of physical comorbidities; that these comorbidities appear early in life; and
that they have a substantial impact on mortality. This information raises concerns about the consequences and
causes of physical disorders in patients with schizophrenia. Additionally, it will help to guide the design and
implementation of preventive and therapeutic programs from the viewpoint of clinical care and in terms of health-
care service planning.
Background
There is growing interest in the effects of physical dis-
ease on patients with schizophrenia. Physical disease can
affect psychiatric signs and symptoms, response to psy-
choactive drugs, life expectancy, and use of healthcare
services [1-5]. However, there is no consensus about
how to treat or prevent physical disease in patients with
schizophrenia [6,7]. This is mainly because of the diffi-
culties involved in selecting and analyzing representative
samples of such patients [8].
In Spain, following psychiatric reform and the de-
institutionalization process in the 1980 s, most people
with schizophrenia live in the community and receive
public universal healthcare in the same centers used by
the general population [9-11]. In this scenario, our
hypothesis is that the study of physical disease in hospi-
talized people with schizophrenia may provide relevant
information for clinical practice and healthcare planning.
The objective of the present study was to examine
physical disease in hospitalized people with schizophre-
nia, describe the epidemiological characteristics, and
identify the most prevalent physical diseases as well as
their impact on mortality by analysis of a national
administrative database.
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This study used the National Hospital Discharge Regis-
try of Spain, the official database of the Ministry of
Health [12]. This information is derived from discharge
reports from all acute-care hospitals, and is representa-
tive of the national population, as it includes data on
over 90% of all annual hospital admissions nationwide.
The registry, mandated by law, includes demographic
data; clinical data, including diagnoses (one main or pri-
mary diagnosis and up to 12 additional diagnoses all of
which are considered as secondary diagnoses) coded
according to the International Classification of Diseases,
9
th Revision, Clinical Modification (ICD-9-CM); dates of
admission and discharge; type of admission; and charac-
teristics and disposition upon hospital discharge.
We used population figures from the 2003-04
National Health Survey [13] to compare physical-disease
prevalence between our study population and the
general population. We also obtained demographic
national population data from the National Statistics
Institute [13].
Period of analysis
We used data from the national database that covered
the period January 1 to December 31, 2004.
Case selection
Cases were selected by identification of codes corre-
sponding to schizophrenia (ICD-9 codes 295.xx), among
hospitalized subjects aged ≥15 years. Afterward, to avoid
an overestimation of comorbidities and outcomes for
each case, we performed a process of filtering and
depuration of the database in which we explored the
number of hospital discharges in the analysis period. To
carry this out, the following identification variables were
chosen: birth date, gender, admission date, discharge
date, postal code and readmission (coded as a binary
variable). In the database refinement process used in
this study, 1,776 cases were identified, within the analy-
sis period, as having been readmitted into the same hos-
pital and with the same main diagnosis. Subsequently,
among the admissions identified for each patient, the
most complete one, in terms of coding with respect to
the coding for the main diagnosis and the secondary
ones, was chosen.
Comorbidities
For each case, physical disease was characterized by
ICD-9 codes: infectious diseases (001-139); neoplasms
(140-239); endocrine diseases (240-279); hematological
diseases (280-289); neurological diseases (320-389); dis-
eases of the circulatory system (390-459); respiratory
diseases (460-519); diseases of the digestive system
(520-579); diseases of the genitourinary tract (580-629);
complications of pregnancy, childbirth, and the puerper-
ium (630-677); diseases of the skin and subcutaneous
tissue (680-709); diseases of the musculoskeletal system
and connective tissue (713-739); and injury and poison-
ing (800-999). Within each category of physical illnesses,
those considered of special clinical relevance, such as
Chronic Obstructive Pulmonary Disease (COPD);
Ischemic Heart Disease (IHD); Myocardial Infarction
(MI) and Diabetes will be analyzed specifically.
In addition, specific codes were used to identify abuse
or dependency on drugs (codes ICD-9: 304.8, 304.2,
305.9), alcohol (305.0, 303.9), and tobacco (305.1,
989.84, E869.4) given their known capacity for generat-
ing or complicating the course of physical disease in
patients with schizophrenia [14]. Finally, to determine
the extent of physical comorbidities of known prognos-
tic value, we used a validated ICD-9 version [15] of the
Charlson comorbidity index [16]. In accordance with
prior literature [17], four different score groups (0, 1-2,
3-4, > 4) were employed.
Ethical issues
The study was exempt from institutional review board
approval, because only de-identified administrative data
were used.
Data analysis
This descriptive study analyzed the prevalence (and 95%
CIs) of selected physical morbidities and their distribu-
tion according to gender and age quartiles. Data are
summarized as frequencies and percentages for categori-
cal variables. Continuous variables are presented as
means and standard deviations (SD). For between-group
comparisons, we used c
2 tests for categorical data. Con-
tinuous variables were analyzed with Snedecor’sFt e s t
or the Mann-Whitney U test. Odds ratios (ORs) with
95% confidence intervals were computed where appro-
priate. We used an exploratory logistic regression
analysis to identify the impact of physical illness upon
in-hospital mortality.
The age-and gender-standardized rates were calculated
by direct standardization based on the 2004 Spanish
population aged ≥15 years [18].
We estimated expected values for mortality by
10 years-age groups based on the 2004 Spanish popu-
lation aged ≥15 years. Observed and expected num-
bers of deaths were used to calculate the standardized
mortality ratios (SMRs) versus the general population
[2]. In order to explore the impact of physical disease
on the risk of death, SMRs were calculated for the
subgroups of cases with/without ICD-9 codes of physi-
cal disease.
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Windows (SPSS Inc., Chicago, IL). A p-value < 0.05 was
considered significant.
Results
Of the 3,951,214 hospital discharges registered in sub-
jects ≥15 years of age across the nation in 2004, and
after carrying out several depuration processes for the
database, 16776 records with schizophrenia were eligible
for analysis (incidence rate 46.23 cases per 100,000
population/year). Of the total number of cases, 64% of
hospitalisations (n = 10745; 29.6 cases per 100,000
population/year) appeared to be directly associated with
schizophrenia, inasmuch as schizophrenia is shown as
the principal diagnosis, whereas in the remaining 36%
(n = 6031; 16.63 cases per 100,000 population/year), the
primary cause of hospitalisation was stated to be some
other disease.
Stratification by age-groups is shown in Figure 1.
As shown in Table 1 hospital admissions were mostly
for acute conditions through emergency departments
and more frequent in men. Mean age of the cases was
43 years and men were significantly younger than
women (41.2 ± 14.7 years vs. 47.9 ± 17 years; p < 0.001).
The mean number of physical ICD-9 codes was 1.22 ±
1.38 (range 0-8), and women had significantly more
codes than men (1.26 ± 1.4 vs. 1.20 ± 1.3; p = 0.002).
Overall, 61% of patients had at least one ICD-9 code,
and 32% had more than one ICD-9 code. Stratification
by age showed that 50% of cases were younger subjects
(15-31 years of age), and that the number of ICD-9
codes increased with age. Thus, for patients aged 53
years or more, 84% had at least one physical ICD-9
code (17% had one code; 24% two codes; and 43% three
or more codes). This increase with age occurred for
both men and women.
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Figure 1 Hospital admissions in patients with schizophrenia. Rates of hospitalizations in patients with schizophrenia in Spain according to
10-year age groups and principal diagnosis at discharge. Overall rate (filled squares/solid line), data for cases with principal diagnosis of
schizophrenia (filled diamonds/dotted line), data for cases admitted due to physical disease (filled triangles/dotted line).
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Page 3 of 10Furthermore, 20% of the cases had Charlson indices
greater than zero, although there was no statistically sig-
nificant difference between the genders. The severity of
this index rose significantly with age, independent of
gender.
Addiction to drugs, alcohol, or tobacco was the most
significant problem, and about one-third of cases had
a code indicating substance abuse or dependency
(Table 2). With respect to defined ICD-9 groups, the
most frequent were endocrine problems, circulatory and
respiratory diseases, and injury-poisoning. Within these
categories, diabetes mellitus and chronic obstructive pul-
monary disease (COPD) were pre-eminent, with an
overall prevalence of 8% and 5.5%, respectively. Ischemic
heart disease was present in 338 cases: of these, 185 had
myocardial infarction, corresponding to an overall pre-
valence of 1.1% (95% CI: 0.94-1.26).
The number of cases in all ICD-9 groups increased
with age. In the case of endocrine and circulatory
diseases, almost 40% of the population over the age of
53 was affected. In addition, there were gender-related
differences in the prevalence of several ICD-9 groups
(Table 3).
Approximately 13% of cases (n = 2,210) underwent
surgical procedures during hospitalization, where diges-
tive (n = 349) and musculoskeletal (n = 351) procedures
were the most common.
A comparison between our data and the official data
for the Spanish population provided by the National
Health Survey [13] indicate that diabetes rates are
clearly higher, twice as high in the case of women, than
those observed for the general Spanish population
(5.02% overall, 5.29% in women and 4.73% in men). The
frequency of neoplasms observed in our study is also
higher than that reported in the population data for
Spain (2.37% overall, 1.92% in men and 2.79% in
women). Similarly, our cases register a higher rate of
tobacco and alcohol abuse/dependence than does the
Table 1 Global characteristics of the population
Total Men Women
Cases 16776 10952 (65%) 5818 (35%)
Hospital admission:
Acute 14 699 (88%) 9625 (88%) 5069 (87%)
Scheduled 2066 (12%) 1320 (12%) 745 (13%)
Schizophrenia in principal diagnosis at hospital discharge 10 745 (64%) 7209 (66%) 3532 (61%)
Age, years 43.5±16 41.2±14.8 47.9±17.2
Age, decades
15-24 years 1483 (8.8%) 1149 (10.5%) 333 (5.7%)
25-34 years 4054 (24,2%) 2938 (26.8%) 1114 (19.1%)
35-44 years 4560 (27.2%) 3122 (28.5%) 1437 (14.7%)
45-54 years 2784 (16.6%) 1754 (16%) 1030 (17.7%)
55-64 years 1699 (10.1%) 963 (8.8%) 735 (12.6%)
65-74 years 1350 (8%) 718 (6.6%) 632 (10.9%)
75-84 years 680 (4.1%) 270 (2.5%) 409 (7%)
≥85 years 166 (0.99%) 38 (0.3%) 128 (2.2%)
Mean ICD-9-CM codes 1.22±1.38 1.20±1.34 1.26±1.46
Number of codes:
1 4914 (29%) 3482 (31.8%) 1430 (24.6%)
2 2549 (15%) 1660 (15.2%) 889 (15.3%)
3 1451 (9%) 879 (8.0%) 571 (9.8%)
4 771 (5%) 461(4.2%) 310 (5.3%)
≥5 548 (3.3%) 330 (3.1%) 218 (3.8%)
Mean Charlson Index 0.43±1.26 0.43±1.28 0.43±1.20
Charlson Index (categorized)
0 points 13 518 (81%) 8912 (81.4%) 4602 (79.1%)
1,2 points 2559 (15%) 1561 (14.3%) 996 (17.1%)
3,4 points 274 (2%) 183 (1.7%) 91 (1.6%)
>4 points 425 (2.5%) 296 (2.7%) 129 (2.2%)
Data are shown as mean ± standard deviation or number of cases and percentages (%)
The differences between the some of the gender data and the total population are due to missing values.
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Page 4 of 10general Spanish population with 12.8% and 2.55% of the
population (4.5% of men and 0.6% of women) being
classified as heavy smokers and excessive drinkers
respectively, and also a high rate of AIDS (1.61 per 1000
population). On the other hand, we found no pro-
nounced differences in the frequency of COPD (5.33%
in the overall Spanish population) and ischemic heart
disease (2.39% overall, 3.2% in men and 1.62% in
women).
Regarding outcomes, 88% of the cases (n = 14,701)
returned home; 6.2% (n = 1,036) were transferred to
other hospitals; 2.1% (n = 356) were transferred to a
socio-health care center; and 2.3% (n = 387) died in hos-
pital. No significant differences were observed in hospi-
tal mortality rates between women and men (2.6% vs.
2.1%; OR: 1.22, 95% CI: 0.99-1.50). The mean age of
patients who died was 63 years. For men and women
there were statistically significant differences in mortal-
ity according to age, with a rise in mortality after the
age of 40. The mortality in cases without an associated
physical illness is 0.2% (n = 12) while that in cases with
one or more codes of physical disease is 3.7% (n = 375).
Furthermore, cases with schizophrenia as the main
discharge diagnosis presented a hospital mortality of
0.3% (n = 27 cases), whereas that in cases with physical
illness in the primary diagnosis was of 6% (n = 360
cases). The distribution of the main discharge diagnoses
by gender is shown in Table 4.
To investigate factors associated with in-hospital mor-
tality, we performed an exploratory logistic regression
analysis which included gender, age-quartiles, ICD-9
main diagnostic blocks at discharge, and categorized
Charlson index scores. The results indicated that the
risk of in-hospital death was significantly correlated with
age, Charlson index score, and several main ICD-9
codes of physical disease (Table 5). There were no sig-
nificant interactions between these variables (p = 0.094).
Moreover, there were no significant differences by gen-
der in mortality after controlling for age, Charlson
Index, and ICD categories.
Our study found 387 observed deaths, whereas
expected deaths based on general population estimates
for the same calendar time amount to 167 [13]. The cal-
culated average SMR is 2.32 (95%CI: 2.09-2.56).
Table 2 Frequency of specific ICD-9 physical diseases
ICD-9-CM groups No. cases, % and (95% CI)
Substance abuse/dependency 4899, 29 (28.5-29.9)
Tobacco 2533, 15 (13.6-16.4)
Alcohol 1745, 10.4 (9.9-10.9)
Drugs 2377, 14.2 (13.6-14.7)
Endocrine, nutritional and metabolic diseases 2772, 16.5% (15.9-17.1)
Diabetes 1339, 8% (6.54-9.44)
Diseases of the Circulatory System 2458, 14.7% (14-15.2)
Ischemic heart disease 338, 2% (0.55-3.6)
Cardiac failure 260, 1.5% (1.36-1.74)
Cerebrovascular Disease 257, 1.5% (1.35-1.72)
Diseases of the Respiratory System 2056, 12.3% (11.8-12.8)
COPD 926, 5.5% (5.17-5.87)
Injury-Poisoning 1901, 11.3% (9.89-12.73)
Diseases of the Digestive System 1749, 10.4% (9.96-10.9)
Hepatic 57, 0.3% (0.25-0.43)
Diseases of the Nervous System 1401, 8.4% (7.9-8.8)
Dementia 130, 0.8% (0.64-0.91)
Diseases of the Genitourinary System 1168, 7% (6.6-7.4)
Renal Insufficiency 172, 1% (0.87-1.18)
Infectious and parasitic diseases 1095, 6.5% (6.2-6.9)
AIDS 190, 1.1% (0.97-1.29)
Neoplasms 746, 4.4% (4.1-4.8)
Diseases of the Blood and blood-forming organs 724, 4.3% (4.0-4.3)
Diseases of the Skin and Subcutaneous Tissue 540, 3.2% (2.9-3.5)
Diseases of the Musculoskeletal & Connective Tissue 552, 3.3% (3.0-3.6)
Complications of pregnancy, childbirth and the puerperium 113, 1.94% (1.6-2.3)
ICD-groups are ordered by descending counts. CI95%: Confidence interval
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Page 5 of 10Table 3 Frequency of physical diseases in males and females
ICD-9-CM groups Men (% of cases) Women (% of cases) OR
1 (95% CI), p-value
Substance abuse/dependency 37 15 3.28 (3.02-3.56), <0.001
Tobacco 13.8 3.9 3.9 (3.4-4.5), <0.001
Alcohol 19 5.1 4.35 (3.9-4.9), <0.001
Drugs 18 9.9 1.9 (1.8-2.2), <0.001
Endocrine, nutritional and metabolic diseases 13.6 22.1 0.55 (0.51-0.6), <0.001
Diabetes 6.3 11 0.57 (0.51-0.64), <0.001
Diseases of the Circulatory System 13.2 17.4 0.7 (0.66-0.8), <0.001
Ischemic heart disease 2.3 1.4 1.67 (1.3-2.15), <0.001
Cardiac failure 1.3 1.9 0.74 (0.58-0.96), 0, 019
Cerebrovascular Disease 1.2 2.2 0.54 (0.42-0.7), <0.001
Diseases of the Respiratory System 12.7 11.5 1.12 (1-1.2), 0.022
COPD 6.4 3.8 1.74 (1.5-2.03), <0.001
Injury-Poisoning 10.6 12.7 0.82 (0.74-0.91), <0.002
Diseases of the Digestive System 10.7 9.9 1.09 (1-1.2), 0.106
Hepatic 0.9 0.3 2.7 (1.65-4.42), <0.001
Diseases of the Nervous System 7.8 9.4 0.8 (0.73-0.91), <0.001
Dementia 0.5 1.3 0.36 (0.26-0.52), <0.001
Diseases of the Genitourinary System 5.6 9.5 0.57 (0.5-0.64), <0.001
Renal Insufficiency 1 1.1 0.87 (0.64-1.2), 0.39
Infectious and parasitic diseases 6.9 6.9 1 (0.88-1.14), 0.99
AIDS 1.3 0.8 1.7 (1.23-2.4), <0.001
Neoplasms 3.8 5.7 0.65 (0.56-0.75), <0.001
Diseases of the Blood and blood-forming organs 3.5 5.9 0.57 (0.49-0.66), <0.001
Diseases of the Skin and Subcutaneous Tissue 3.1 3.4 0.9 (0.75-1.08), 0.245
Diseases of the Musculoskeletal and Connective Tissue 2.6 4.5 0.65 (0.56-0.75), <0.001
1OR for men versus women. OR: Odds Ratio. CI: Confidence interval
Table 4 In-hospital deaths: Main discharge diagnosis by gender
ICD-9-CM main diagnostic categories at discharge Number of cases
Total (n = 387) Men (n = 235) Women (n = 152)
Schizophrenia 27 21 6
Physical disease:
Diseases of the Circulatory System 73 36 37
Diseases of the Respiratory System 71 45 26
Neoplasms 68 46 22
Injury-Poisoning 43 21 22
Diseases of the Digestive System 36 22 14
Infectious and parasitic diseases 19 15 4
Diseases of the Nervous System 12 9 3
Endocrine, nutritional and metabolic diseases 11 4 7
Diseases of the Genitourinary System 7 4 3
Diseases of the Musculoskeletal and Connective Tissue 5 4 1
Diseases of the Blood and blood-forming organs 5 2 3
Others. Miscellaneous 10 6 4
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to the general population was disproportionately higher
in the subgroup of cases with physical disease (Figure
2). In fact, the calculated overall SMR in this group of
cases is 3.68 (95%CI: 3.31-4.07).
Discussion
This study is, to the best of our knowledge, one of the
first to provide nationally representative estimates of the
prevalence and characteristics of physical disease in hos-
pitalized patients with schizophrenia in Spain. Our
results indicate that schizophrenia is associated with a
substantial burden of physical comorbidities; that these
comorbidities appear early in life; and that they have a
severe impact on mortality. Also, in agreement with
prior reports [3,4,19,20], our data indicate that hospita-
lized schizophrenic individuals often have numerous
physical diseases, and that several of these diseases are
of known clinical severity and prognostic relevance,
however, the study design do not allow us for making
causal inferences.
As for the most prevalent ICD-9 groups, our data were
in general agreement with international figures. Thus, the
rates of endocrine, circulatory, respiratory, and digestive
diseases in our population were comparable to those in
other studies that analyzed whole populations or used
administrative data [19,21,22]. Certain physical diseases
(substance abuse, injury-poisoning, and infections such as
A I D S )w e r em u c hm o r ef r e q u e n ti ny o u n gp e o p l e
[20,23]. In contrast, circulatory and endocrine diseases
were more common in patients over the age of 40 years.
Our data also identify gender-related differences in the
physical diseases of patients with schizophrenia. Thus,
compared with women, men had significantly higher
rates of substance abuse (alcohol, drugs, and cigarette-
smoking [24]), and a higher prevalence in certain diag-
nostic groups, such as chronic respiratory processes,
digestive diseases, and infectious diseases [6,23,25].
Although men had a lower overall risk of circulatory
disease, they suffered more from ischemic heart disease
and myocardial infarction. On the other hand, women
were more likely to have endocrine diseases, musculos-
keletal and connective tissue diseases, neurological dis-
eases, and neoplasms, possibly related to their older age
[25-27].
The results of our study add to the existing contro-
versy about differences in the rates of physical illnesses
in patients with schizophrenia compared to the general
population [1,7]. Thus, a comparison of our data and
official figures for the Spanish general population
Table 5 Factors related to in-hospital mortality
Exp (B) (95% CI Exp B), p value
Gender
Male Reference group
Female 1.01 (0.81-1.27); 0.87
Age range (quartiles)
15-31 years Reference group
32-40 years 1.49 (0.76-2.94); 0.246
41-53 years 2.67 (1.45-4.91); 0.002
>53 years 6.14 (3.40-11.06);<0.001
ICD-9-CM main diagnostic categories at discharge
Diseases of the Respiratory System 3.54 (2.8-4.48);<0.001
Neoplasms 2.17 (1.52-3.11);<0.001
Diseases of the Circulatory System 2.16 (1.70-2.75);<0.001
Infectious diseases 1.80 (1.36-2.38);<0.001
Diseases of the Digestive System 1.77 (1.39-2.26); <0.001
Injury and Poisoning 1.57 (1.19-2.07); <0.001
Diseases of the Nervous System 1.45 (1.1-1.89); 0.007
Charlson Index (categorized)
0 points Reference group
1-2 points 1.33 (1.01-1.76);0.045
3-4 points 1.76 (1.21-2.78); 0.01
>4 points 3.55 (2.29-5.52);<0.001
CI: Confidence interval.
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Page 7 of 10provided by the National Health Survey [13] suggests
that subjects with schizophrenia have higher rates of
substance abuse/dependency, diabetes mellitus, diges-
tive diseases, neoplasms, and AIDS. On the other
hand, we found no pronounced differences in the fre-
quency of COPD and ischemic heart disease. These
findings, though noteworthy in view of the high preva-
lence of related risk factors, such as diabetes and
smoking, are comparable to results of previous studies.
Thus, Carney and colleagues [19] found that whereas a
somewhat higher percentage of persons with schizo-
phrenia had ischemic heart disease than did controls
from the general population (2.3% vs.1 . 9 % ) ,t h e
adjusted odds ratio was not significant. Regarding
COPD, our data also agree with previous reports [25].
However, it should be noted that diagnosis of early-
stage COPD can be difficult [28] and the reported rate
of COPD may be biased by a failure to perform diag-
nostic spirometry [29]. In addition, a tendency to
ignore a diagnosis of COPD in patients with schizo-
phrenia has been reported [30].
Concerning mortality, this study highlights the impact
of physical disease on the risk of death in people with
schizophrenia. Our analysis indicates that the Charlson
index score and the presence of certain physical diseases
(e.g., respiratory, circulatory, tumoral, infectious, diges-
tive, and injury-poisoning) significantly increase the risk
of death during hospitalization. In addition, our data
underscore that physical disease in schizophrenia was
associated to disproportionately high mortality risks
relative to the general population. These results, that
agree with prior reports [2,31-33], raise concerns about
the consequences and causes of physical disorders in
patients with schizophrenia and identify a compelling
need for a specific approach aimed to detect physical
comorbidities, especially those that are most common
and closely related to mortality. In this regard, the high
risk of mortality from respiratory diseases in our popu-
lation suggests that a specific approach be used to moni-
tor and control modifiable risk factors, such as smoking
[34]. Furthermore, as the prevalence and the type
of physical comorbidity show significant differences
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Page 8 of 10between both genders, the preventive and therapeutic
measures to reduce such a disease burden and asso-
ciated mortality must, in addition, have a specific gender
orientation.
Our study was observational, and thus we cannot defi-
nitely identify the influence of factors linked to lifestyle,
adverse drug effects, or socio-economic level to explain
the pattern of physical diseases in our population. Like-
wise, it is impossible for us to analyze the adequacy of
healthcare received by the patients. Several authors have
suggested that people with schizophrenia may receive
inadequate medical treatment and experience inequal-
ities and difficulties in accessing various medical proce-
dures, even when free and universal healthcare is
available, as in Spain, at the point of care [35,36].
The results of this study extend previous work by pro-
viding a comprehensive overview of medical disorders
associated with schizophrenia. In particular, our study
has several strengths compared to previous reports: (a)
we characterized physical diseases in a large population-
based representative sample of patients with schizophre-
nia; and, (b) we included all diseases and objectively
classified them according to the ICD-9 system. In addi-
tion, our data represent clinical practice patterns for
professionals nationwide, allowing us to generalize the
results. Furthermore, the use of the Charlson comorbid-
ity index, which is widely used to predict hospitalization
outcome, increases the validity of observations.
We must also acknowledge possible limitations of our
work. This study is subject to the limitations inherent in
retrospective studies using administrative databases.
Data from these databases lack of many measures
obtainable only from chart review or survey with the
attendant potential for omitting important prognostic
factors. Furthermore, these data do not allow causal
inferences to be made. However, the use of such data-
bases is well-established in psychiatric epidemiology and
health services research and has been shown to furnish
valuable information for assessing the need for preven-
tive and therapeutic care and for service planning
[37-39]. Additionally, the Spanish Ministry of Health
[12] systematically performs assurance audits of the
National Hospital DischargeR e g i s t r yt ov e r i f yc o d i n g
adequacy. Moreover, we followed the guidelines for
reporting observational studies, as outlined by the
STROBE Initiative [40].
We also recognize that the presence of a control
group would have resulted in more far-reaching results
and a more precise determination of the risk and time
of development of physical comorbidities in patients
with schizophrenia. Currently, however, it was not possi-
ble for us to consider a sufficiently large control group
representative of the patients studied. Nevertheless,
given that, to our knowledge, this work constitutes the
first study with this range of diagnosis and population
size carried out in our country, we hope that our results
will be the base of other studies with a stronger metho-
dological design.
Finally, it is inarguable that hospitalized subjects will
have a disease load and severity greater than the outpa-
tient population. However, our results clearly show the
distribution and prevalence of different physical diseases
that can contribute to the deterioration of health, caus-
ing patients to be admitted into hospital and increasing
their risk of death. As with several recent studies
[36,41], our results have implications for the design of
preventive and therapeutic programs and services for
people with schizophrenia that aim to reduce the preva-
lence and negative impacts of physical diseases in this
population.
Conclusions
In summary, we analyzed a nationwide database to
determine the prevalence and characteristics of physical
diseases in hospitalized patients with schizophrenia. Our
results indicate that physical illness is a major burden
for such patients, that these comorbidities appear early
in life and that they have a serious impact on mortality.
This information raises concerns about the conse-
quences and causes of physical disorders in patients
with schizophrenia and may prove useful in the design
and implementation of preventive and therapeutic pro-
grams and for health-care service planning.
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